Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999

Therapeutic Innovation & Regulatory Science

Volumn 35, Issue 1, 2001, Pages 293-317

  Fung, Man ^a,b   Thornton, Anna ^a   Mybeck, Kathy ^a   wu, Jasmanda Hsiao Hui ^a   Hornbuckle, Ken ^a   Muniz, Edmundo ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Worldwide Pharmacovigilance and Epidemiology   (Taiwan)

Author keywords

Adverse drug reactions; Market discontinuation; Market withdrawal; Postmarketing surveillance

Indexed keywords

EID: 84996249312     PISSN: 21684790     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150103500134     Document Type: Article

References (165)

1. Wilford BB, Finch J, Czechowicz DJ, Warren D. An overview of prescription drug misuse and abuse: defining the problem and seeking solutions. J Law Med Ethics. 1994; 22: 197–203.
2. Charpak Y, Favre I, Bloch J, Jauffret M, Maire A. Dependence, abuse and misuse of drugs: knowledge and attitudes of private physicians in the Ile-de-France. Rev Epidem et Sante Publ. 1999; 47: 239–247.
3. Boyle FM Adverse interaction of herbal medicine with breast cancer treatment. Med J Australia. 1997; 167: 286.
4. Mann RD Monitoring the Safety of Medicine. In: Luscombe D, Stonier PD, eds. Clinical Research Manual. Haslemere, England: Euromed Communications; 1994: 8.1–8.42.
5. Flectcher AP Post-Marketing Surveillance. In, Luscombe D, Stonier PD, eds. Clinical Research Manual. Haslemere, England: Euromed Communications; 1998: 15.1–15.26.
6. Faich GA, Dreis M, Tomita D. National adverse drug reaction surveillance. Arch Int Med. 1998; 148: 785–787.
7. Anello C. Management of ADR reports at the FDA. Drug Inf J. 1985; 19: 291–294.
8. Gordon AJ, Petrick RJ Worldwide regulations for manufacturers on clinical safety surveillance of drugs. Drug Inf J. 1992; 26: 1–15.
9. Griffin JP Survey of spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharm. 1986; 22: 83S–100S.
10. Albengres E. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs. J Rheumatol. 1988; 15: 20–23.
11. Sachs RM, Bortnichak EA An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med. 1986; 81: 49–55.
12. Fletcher AP Spontaneous adverse drug reaction reporting vs. event monitoring: a comparison. J Roy Soc Med. 1991; 84: 341–344.
13. Mann RD Managing adverse reaction information. Drug Inf J. 1992; 26: 583–587.
14. Dangoumau J, Lagier G, Royer RJ A drug information-ADR collection network: the French system. Drug Inf J. 1986; 20: 337–346.
15. Talbot JCC Management of ADR data from different sources. Drug Inf J. 1986; 20: 297–299.
16. Koch-Weser J. International aspects of spontaneous reporting of adverse drug reactions. Drug Inf J. 1985; 19: 217–221.
17. Rawlins MD Spontaneous reporting of adverse drug reactions I-II: the data and uses. Br J Clin Pharmacol. 1988; 26: 1–11.
18. Weisberg E. Contraceptive choices—turning back the clock. Adv Contraception. 1991; 7: 115–127.
19. Welty TE, Privitera M, Shukla R. Increased seizure frequency associated with felbamate withdrawal in adults. Arch Neurol. 1998; 55: 641–645.
20. Ashworth L. Is my antihistamine safe? Home Care Provider. 1997; 2: 117–120.
21. Bouvier-Colle MH Drugs: 10 years of recall from the market. Rev Epidem et Sante Publ. 1994; 42: 466–467.
22. Lynn NJ, Ellis JM Pharmacists’ liability into the year 2000. J Am Pharm Assoc. 1998; 38: 747–752.
23. Burkhart GA, Sevka MJ, Temple R, Honig PK Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharm Therap. 1997; 61: 93–96.
24. Kleinke JD, Gottlieb S. Is the FDA approving drugs too fast? Probably not—but drug recalls have sparked debate. Br Med J. 1998; 317: 899.
25. Miller HI When is a drug ‘safe'? Nature. 1990; 344: 698.
26. Jefferys DB, Leakey D, Lewis JA, Payne S, Rawlins MD New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol. 1998; 45: 151–156.
27. Bakke OM Drug withdrawals—circumstances and market impact. In: Cato AE, ed. Clinical Drug Trials and Tribulations. New York & Basle: Marcel Dekker Inc.; 1988: 377–395.
28. McGhan WF, Block LH An analysis of drug recalls and court actions in the United States Pharmaceutical Industry. Pharm Med. 1986; 1: 187–193.
29. Anonymous. 1996 product withdrawals in France. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; July 25, 1997; 2252: 1.
30. Anonymous. Rate of drug recalls rises sharply—FDA ‘fast track’ approval called into question. NBC Internet News. June 24, 1999. www.msnbc.com/news.
31. Steward F, Wibberley G. Drug innovation— what's slowing it down? Nature. 1980; 284: 118–120.
32. Goyan JE The role of evidence in the approval of pharmaceuticals. Ann NY Acad Sci. 1993; 703: 275–277.
33. Weintraub M, Northington FK Drugs that wouldn't die. JAMA. 1986; 255: 2327–2328.
34. Spriet-Pourra C, Auriche M. Drug Withdrawal from Sale. 2nd Edition. Scrip Reports. Richmond, UK: PJB Publications Ltd.; 1994.
35. Bakke OM, Wardel WM, Lasagna L. Drug discontinuation in the United Kingdom and Untied States, 1964 to 1983: issues of safety. Clin Pharm Therap. 1984; 35: 559–567.
36. Lindstrom LH The effect of long-term treatment with clozapine in schizophrenia: in 96 patients treated with clozapine for up to 13 years. Acta Psych Scand. 1988; 77: 524–529.
37. Bourgeois BF Felbamate. Semin Ped Neurol. 1997; 4: 3–8.
38. Blum DE New drugs for persons with epilepsy. Adv Neurol. 1998; 76: 57–87.
39. Anonymous. BGA wants molsidomine suspension. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Oct. 7, 1985; 1040: 2.
40. Lechat P. Problems raised by the withdrawal from the market of drugs in therapeutic use. Therapie. 1987; 42: 403–410.
41. Brown MA, McCowan LM, North RA, Walters BN Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australian Society for the Study of Hypertension in Pregnancy. Med J Australia. 1997; 166: 640–643.
42. Anonymous. Prescribe reviews French 1996 launches. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Jan. 14, 1997; 2197: 1.
43. Hass AE, Portale DB, Grossman RE New drugs: their market life and safety. Pharm J. 1985; 235–238.
44. Anonymous. Alpidem Suspended in France. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; 1993; 1870: 22.
45. Anonymous. Amineptine: marketing authorization suspended—drug abuse and dependence, France. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Jan. & Feb. 1999; 1&2. www.who.int/dmp/newsletters.
46. Ekeberg O, Jacobsen D, Flaaten B, Mack A. Effect of regulatory withdrawal of drugs and prescription recommendations on the pattern of self-poisonings in Oslo. Acta Med Scand. 1987; 221: 483–487.
47. Anonymous. J&J antihistamine withdrawn. Hismanal taken off shelves. ABC Internet News. June 21, 1999. abcnews.go.com/sections/living/DailyNews.
48. Anonymous. Maker to Discontinue Allergy Drug Hismanal. Washington Post. Online. Jun. 22, 1999. washingtonpost.com/wp-srv/health.
49. Anonymous. Hismanal-worldwide withdrawal. Information for Health Professionals. Malaysia Adverse Drug Reaction Advisory Committee Web site. July 1999. www3.jaring.my/mad.
50. Anonymous. Astemizole prescription only in UK. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; July 8, 1998; 2350: 21.
51. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995; 58: 108–117.
52. Fenner H. Evaluation of the efficacy and safety of NSAIDs. A new methodological approach. Scand J Rheum. 1989; 80(suppl):32–39.
53. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ The safety of newly approved medicines. Do recent market removals mean there is a problem? JAMA. 1999; 281: 1728–1734.
54. Williams P, Williams P, Currie WJ, VandenBurg MJ A double-blind comparison of ‘Osmosin’, benoxaprofen and placebo in the treatment of osteoarthritis. Curr Med Res Opin. 1983; 8(Suppl 2):90–98.
55. Anonymous. Bromfenac sodium capsules (DURACT®) withdrawn from the market. Dear Doctor Letter. Philadelphia, PA: Wyeth Ayerst Company; 1998.
56. Anonymous. Bromfenac (DuractR) withdrawn from the market—severe liver failure. The WHO Information Exchange System. Alert No. 71, Jun. 26, 1998. www.who.int/dmp/Alerts.
57. Anonymous. Bromfenac withdrawn—hepatotoxicity, Saudi Arabia. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & June 1999; 5&6. www.who.int/dmp/newsletters.
58. Anonymous. EC chlormezanone withdrawal confirmed. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Oct. 10, 1997; 2276: 5.
59. Anonymous. Chlormezanone withdrawn because of cutaneous toxicity—update. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Jan. & Feb. 1997; 1&2. www.who.int/dmp/newsletters.
60. Anonymous. Chlormezanone marketing authorization withdrawn, Germany. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Nov. & Dec. 1997; 11&12. www.who.int/dmp/newsletters.
61. Anonymous. Chlormezanone withdrawn, United Arab Emirates. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Mar. & Apr. 1998; 3&4. www.who.int/dmp/newsletters.
62. Anonymous. Chlormezanone withdrawn, Zimbabwe. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Sept. & Oct. 1998; 9&10. www.who.int/dmp/newsletters.
63. Anonymous. Chlormezanone withdrawn, Saudi Arabia. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1999; 5&6. www.who.int/dmp/newsletters.
64. Anonymous. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, Nov. 1997. MMWR. 1997; 46: 1061–1066.
65. Anonymous. Warning not to use products containing fenfluramine (Ponderal, Ponderax) or dexfenfluramine (Redux). Health Canada Web site. Sept. 15, 1997. www.hc-sc.gc.ca.
66. Anonymous. Withdrawal of fenfluramine (Ponderax) and dexfenfluramine (Adifax). The Medicines Control Agency Web site. www.open.gov.uk/mca.
67. Anonymous. Fenfluramine and dexfenfluramine. The European Agency for the Evaluation of Medicinal Products Press Release. The EMEA Web site. Sept. 9, 1999. www.eudra.org/emea.html.
68. Anonymous. Fenfluramine and dexfenfluramine. Information for Health Professionals. Malaysia Adverse Drug Reaction Advisory Committee Web site. www3.jaring.my/mad.
69. Anonymous. Fenfluramine and dexfenfluramine withdrawn—cardiotoxicity (USA). The WHO Information Exchange System. Alert No. 63, Sept. 16, 1997. www.who.int/dmp/Alerts.
70. Anonymous. Fenfluramine and dexfenfluramine withdrawn, India. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1998; 5&6. www.who.int/dmp/newsletters.
71. Anonymous. Fenfluramine and dexfenfluramine: withdrawn: Saudi Arabia. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1999; 5&6. www.who.int/dmp/newsletters.
72. Anonymous. Diet drugs pulled off the market. The Wall Street Journal Internet News. Sept. 15, 1997. interactive.wsj.com/dailyedition.
73. Anonymous. Withdrawal of oxyphenisatin acetate, diacetoxydiphenolisatin and triacetyldiphenolisatin from the Australian market. Med J Australia. 1972; 1: 1051–1053.
74. Mihajlovic G. Recall of metamizole from the market in countries with modern pharmacotherapy. Srpski Arhiv Za Celokupno Lekarstvo. 1996; 124: 44–46.
75. Anonymous. Metamizole sodium—prohibited, Nepal. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Nov. & Dec. 1997; 11&12. www.who.int/dmp/newsletters.
76. Anonymous. Metamizole sodium—withdrawn due to agranulocytosis, Zimbabwe. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Sept. & Oct. 1998; 9&10. www.who.int/dmp/newsletters.
77. Anonymous. Metamizole sodium—withdrawn due to agranulocytosis, Yemen. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Jan. & Feb. 1999; 1&2. www.who.int/dmp/newsletters.
78. Anonymous. Metamizole sodium—marketing authorization suspended, Sweden. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1999; 5&6. www.who.int/dmp/newsletters.
79. Anonymous. Withdrawal of medicinal products containing ebrotidine—liver toxicity. The WHO Information Exchange System. Alert No. 72, Jul. 29, 1998. www.who.int/dmp/Alerts.
80. Anonymous. Bristol-Myers Squibb (BMS) Enkaid withdrawn in US. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Sep. 25, 1991; 1654: 20.
81. Anonymous. Fenfluramine—withdrawn. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Mar. & Apr. 1998; 3&4. www.who.int/dmp/newsletters.
82. Beasley R, Pearce N, Crane J, Burgess C. Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic. Int Arch Allerg Immun. 1995; 107: 325–327.
83. Crane J, Pearce N, Flatt A, et al., Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet. 1989; 1: 917–922.
84. Anonymous. Glaxo pulls antibiotic on safety fears. Reuters Internet News. Oct. 27, 1999. www.reuters.com/news.
85. Henry JA, Martin AJ The risk-benefit assessment of antidepressant drugs. Med Toxic Ad Drug Experience. 1987; 2: 445–462.
86. Anonymous. Ketorolac withdrawn in France. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Jan. 7th/11th, 1994; 1886/87: 27.
87. Anonymous. Ketorolac post marketing surveillance (PMS) study published. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Feb. 16, 1996; 2103: 1.
88. Anonymous. Ketorolac—extension of suspension. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Jan. & Feb. 1997; 1&2. www.who.int/dmp/newsletters.
89. Garcia C. Mianserin agranulocytosis followed by oxitriptan eosinophilia. Nervenarzt. 1992; 63: 303–307.
90. Anonymous. Posicor. Irish Medicines Board Press Release. June 8, 1998. www.imb.ie/news.
91. Anonymous. Mibefradil (Posicor). Information for Health Professionals. Malaysia Adverse Drug Reaction Advisory Committee Web site. www3.jaring.my/mad.
92. Anonymous. Mibefradil (Posicor)—withdrawn from the market: potential harmful interactions. The WHO Information Exchange System. Alert No. 70, Jun. 15, 1998. www.who.int/dmp/Alerts.
93. Anonymous. Roche withdraws hypertension drug from the market. The Wall Street Journal Internet News. Jun. 8, 1998. interactive.wsj.com/dailyedition.
94. Anonymous. Mebefradil—suspended, Germany. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Sept. & Oct. 1998; 9&10. www.who.int/dmp/newsletters.
95. Anonymous. Muzolimine withdrawn in Europe. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Jul. 17, 1987; 1223: 22.
96. Anonymous. Ciba-Geigy implements Coramine withdrawal. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Oct. 4, 1989; 1452: 11.
97. Anonymous. CSM Update. Withdrawal of Nomifensine. Br Med J. 1986; 293: 41.
98. Martlew VJ Immune haemolytic anemia and nomifensine treatment in north west England 1984–85: report of six cases. J Clin Path. 1986; 39: 1147–1150.
99. Delchier JC, Metreau JM, Levy VG, Opolon P, Dhumeaux D. Oxyphenisatin, a laxative responsible for chronic hepatitis and cirrhosis, still marketed in France. Nouvelle Presse Medicale. 1979; 8: 2955–2958.
100. Anonymous. Liver complications result in withdrawal of attention deficit hyperactivity disorder drug cylert. Health Canada Web site. Sept. 22, 1999. www.hc-sc.gc.ca.
101. Anonymous. Volital (pemoline) has been withdrawn. The Medicines Control Agency Web site. www.open.gov.uk/mca.
102. Anonymous. Pemoline withdrawn—hepatotoxicity, UK. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Nov. & Dec. 1997; 11&12. www.who.int/dmp/newsletters.
103. Brunner FP, Seiwood NH End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee. Nephrol Dial Transplant. 1994; 9: 1371–1376.
104. Pommer W, Glaeske G, Molzahn M. The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences. Clin Nephrol. 1986; 26: 273–278.
105. McGuinness ME, Talbert RL Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmaco. 1993; 27: 1183–1187.
106. Anonymous. Malaysia withdraws prenylamine registrations. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Nov. 9, 1988; 1359: 19.
107. Anonymous. Proxibarbal: voluntary withdrawal. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1998; 5&6. www.who.int/dmp/newsletters.
108. Anonymous. UK suspends Lundbeck's antipsychotic treatment. Health News Daily. Dec. 7, 1998. www.medicalnetinc.com/reuters.
109. Anonymous. Notification of suspension of Serdolect (sertindole). Irish Medicines Board. Dear Doctor Letter. Nov. 23, 1998. www.imb.ie/news.
110. Anonymous. Suspension of availability of sertindole. The Medicines Control Agency Web site. www.open.gov.uk/mca.
111. Anonymous. Sertindole (Serdolect) suspended—cardiac arrhythmias and sudden cardiac death. The WHO Information Exchange System. Alert No. 78, Dec. 4, 1998. www.who.int/dmp/Alerts.
112. Anonymous. Sorivudine & nevirapine on FDA panel. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; May 21, 1996; 2130: 1.
113. Davey P, McDonald T. Postmarketing surveillance of quinolones, 1990 to 1992. Drugs. 1993; 45(Suppl 3):46–53.
114. Anonymous. Temafloxacin-anatomy of a withdrawal. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; 1992; 1737: 20–21.
115. Anonymous. Hoechst Marion Roussel (HMR) withdraws Seldane in US. SCRIP World Pharmaceutical News. London, UK: PJB Publications Ltd.; Feb. 1998; 2298: 1.
116. Anonymous. Terfenadine suspension & restricted use. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Mar. & Apr. 1997; 3&4. www.who.int/dmp/newsletters.
117. Anonymous. Terfenadine prohibited. The WHO Pharmaceuticals Newsletter—Regulatory Actions, May & Jun. 1998; 5&6. www.who.int/dmp/newsletters.
118. Anonymous. Terfenadine withdrawn—cardiotoxicity, Saudi Arabia. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1999; 5&6. www.who.int/dmp/newsletters.
119. van der Klauw MM, van Rey FJ, Stricker BH Polymorph ventricular tachycardia with torsades de pointes caused by administration of terodiline (Mictrol). Nederlands Tijdschrift voor Geneeskunde. 1992; 136: 91–93.
120. Edwards RI, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990; 336: 156–158.
121. Haberle DA, Davis JM, Kawabata M, Metz C, Wapler P, Stachl M. Renal and single-nephron function is comparable in thiobutabarbitone- and thiopentone-anaesthetised rats. Pflugers Archive—Eur J Physiol. 1993; 424: 224–230.
122. Barclay WR Ticrynafen's withdrawal from the market. JAMA. 1980; 243: 771.
123. Finkle MJ Anatomy of drug withdrawals in the United States. In: Cato AE, ed. Clinical Drug Trials and Tribulations. New York & Basle: Marcel Dekker Inc.; 1988: 363–375.
124. Marcus CJ, Griffin JP New chemical entities 1972–1982: licensing and subsequent adverse reactions. AUK/US comparison. Pharm Int. 1984; 5: 146–149.
125. Anonymous. Liver complications reported with anti-Parkinson's drug Tasmar. Health Canada Web site. Nov. 23, 1998. www.hc-sc.gc.ca.
126. Anonymous. Notification of withdrawal of Tasmar. Irish Medicines Board. Dear Doctor Letter. Nov. 23, 1998. www.imb.ie/news.
127. Anonymous. Withdrawal of Tasmar (tolcapone) from the market. The Medicines Control Agency Web site. www.open.gov.uk/mca.
128. Anonymous. Recommendation for the suspension of the marketing authorization for Tasmar. The European Agency for the Evaluation of Medicinal Products Press Release. The EMEA Web site. Nov. 17, 1998. www.eudra.org/emea.html.
129. Anonymous. Tolcapone (Tamar)—liver failure: suspension & warnings. The WHO Information Exchange System. Alert No. 75, Nov. 21, 1998. www.who.int/dmp/Alerts.
130. Anonymous. Tolcapone withdrawn—hepatotoxicity, Australia. The WHO Pharmaceuticals Newsletter—Regulatory Actions. May & Jun. 1999; 5&6. www.who.int/dmp/newsletters.
131. Anonymous. Tolrestat withdrawn—hepatic necrosis. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Mar. & Apr. 1997; 3&4. www.who.int/dmp/newsletters.
132. Meyboom RH The Halcion affair in 1979, a false alarm? Nederlands Tijdschrift voor Geneeskunde. 1989; 133: 2185–2190.
133. Meyboom RH Secondary effects of drugs. The 1979 Halcion experience in the Netherlands, a false alarm? Therapie. 1991; 46: 373–377.
134. Nazareth I, Ashworth M, Hammond J, King M. Withdrawal of triazolam's product licence: effect on patients 18 months later. Addiction. 1995; 90: 927–934.
135. Brahams D. Medicine and the law. Triazolam suspended. Lancet. 1991; 338: 938.
136. Anonymous. Trovafloxacin & alatrofloxacin—suspension and warnings: hepatotoxicity. The WHO Information Exchange System. Alert No. 86, Jun. 18, 1999. www.who.int/dmp/Alerts.
137. Anonymous. Trovafloxacin & alatrofloxacin—suspension and warnings. Information for Health Professionals. Malaysia Adverse Drug Reaction Advisory Committee Web site. July 1999. www3.jaring.my/madrac.
138. Anonymous. Diabetes drug spurs worries about safety. The Wall Street Journal Internet News. Dec. 1, 1997. interactive.wsj.com/dailyedition.
139. Anonymous. Troglitazone (Romozin) withdrawn. The Medicines Control Agency Web site. www.open.gov.uk/mca.
140. Goyan JE. Withdrawal of a drug from the market. What should the prescriber do? JAMA. 1993; 270: 1976–1977.
141. Levy DB, Vasilomanolakis EC Anaphylactic reaction due to zomepirac. Drug Intel Clin Pharm. 1984; 18: 983–984.
142. Speirs CJ Comparison of the safety of several nonsteroidal anti-inflammatory drugs currently or formerly marketed in the United Kingdom. J Clin Pharmacol. 1988; 28: S8–S12.
143. Patton WN, Duffull SB Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance. Drug Safety. 1994; 11: 445–462.
144. Heimpel H. When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed? Eur J Haematol. 1996; 60(suppl):11–15.
145. Knapp DE, Robinson JI, Britt AL Annual adverse drug experience report: 1995. The FDA Web site. www.fda.gov/cder/aers/index.htm.
146. Touw DJ Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Met Drug Int. 1997; 14: 55–82.
147. Jefferson JW Drug and diet interactions: avoiding therapeutic paralysis. J. Clin Psych. 1998; 59(Suppl 16):31–39.
148. Stirling D, Sherman M, Strauss S. Thalidomide: A surprising recovery. J Am Pharm Assoc. 1997; 37: 306–313.
149. Schuler U, Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Safety. 1995; 12: 364–369.
150. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Derm. 1996; 35: 969–979.
151. Koren G, Pastuszak A. How to ensure fetal safety when mothers use isotretinoin (Accutane). Can Fam Phy. 1997; 43: 216–219.
152. Montero D, Moore N, Coulson R, et al., Electronic transmission of rapid alerts in pharmacovigilance: a pilot EC experiment. Pharmacoepi Drug Safety. 1994; 3: 163–167.
153. Kessler DA, Hass AE, Feiden KL, Lumpkin M, Temple R. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan. JAMA. 1996; 276: 1826–1831.
154. Weber JCP Limitations of a voluntary reporting system. In: Hawkins DF, ed. Drugs and Pregnancy; Human Teratogenesis and Related Problems. Edinburgh: Churchill Livingstone; 1983: 31–40.
155. Clark JA, Klincewicz SL, Turner ME, Arellano FM Spontaneous reporting sequences and the Weber effect: a new look at an old phenomenon. Pharmacoepidem Drug Safety. 1999; 8: S95.
156. Fung M, Kwong K, Mockbee C, Hornbuckle K, Muniz E. Analysis of the occurrence of Weber effect in spontaneous adverse event reporting. Pharmacoepidem Drug Safety. 1999; 8: S106.
157. Coppinger PL, Peck CC, Temple RJ Understanding comparisons of drug introductions between the United States and the United Kingdom. Clin Pharmacol Ther. 1989; 46: 139–145.
158. Hayes AH Jr. Safety considerations in product development. Drug Safety. 1990; 5(Suppl 1):24–26.
159. Anonymous. FDA panel recommends continued use of controversial diabetes drug. CNN interactive News. Mar. 26, 1999. cnn.com/HEALTH.
160. Anonymous. FDA places stricter controls on diabetes drug. CAW Interactive News. June 17, 1999. cnn.com/HEALTH.
161. Anonymous. New concerns about side effects of AIDS—fighting protease inhibitors. CNN Interactive News. June 30,1998. cnn.com/HEALTH.
162. Anonymous. HIV protease inhibitors—hyperglycemia. The WHO Pharmaceuticals Newsletter—Regulatory Actions. Nov. & Dec. 1997; 11&12. www.who.int/dmp/newsletters.
163. Anonymous. HIV protease inhibitors revised data sheet-increased blood sugar. The WHO Pharmaceuticals Newsletter—Regulatory Actions. July & Aug. 1998; 7&8. www.who.int/dmp/newsletters.
164. Anonymous. HIV protease inhibitors: lipodystrophy, hyperglycaemia, and nephrolithasis. The WHO Pharmaceuticals Newsletter—Drug Surveillance. July & Aug. 1998; 7&8. www.who.int/dmp/newsletters.
165. Ross-Degnan D, Soumerai SB, Fortess EE, Gurwitz JH Examining product risk in context. Market withdrawal of zomepirac as a case study. JAMA. 1993; 270: 1937–1942.